Supernus Pharm (SUPN) Posts Mixed Q2 Results
Get Alerts SUPN Hot Sheet
Join SI Premium – FREE
Supernus Pharm (NASDAQ: SUPN) reported Q2 EPS of ($5.17), $4.71 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $750 thousand versus the consensus estimate of $70 thousand.
For earnings history and earnings-related data on Supernus Pharm (SUPN) click here.
For earnings history and earnings-related data on Supernus Pharm (SUPN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- CEMEX, S.A.B. de C.V. (CX) Tops Q1 EPS by 5c
- Symrise AG (SY1:GR) (SYIEY) PT Raised to EUR120 at CFRA
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!